Anteris Technologies Global Corp. (AVR)
NASDAQ: AVRHealthcareMedical DevicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
AVR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $664.67M
- EPS (TTM)
- -$1.89
- Dividend yield
- None
- 52-week range
- 3.30 – 11.06
- Day range
- 6.76 – 7.08
- Volume / Avg
- 2.45M / 888.81K
- Beta
- —
- Shares outstanding
- 97.46M
- Next earnings
- Nov 12, 2026
52-week range
AVR stock today
Anteris Technologies Global (AVR) closed at $6.82 on Oct 7, down 3.26% (-$0.23), versus the S&P 500's 0.22% decline. Volume was 2.8x the average at 2.45M shares, a sign of unusually heavy trading. Shares are 38.3% below their 52-week high of $11.06, set on Jul 6, 2026 and 106.7% above the 52-week low of $3.30, in the middle of the past year's range.
AVR is up 36.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 56.1%. Anteris Technologies Global has posted a net loss over the last twelve months (EPS of -$1.89), so its P/E ratio is not meaningful. Anteris Technologies Global's next earnings report is expected on Nov 12, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Anteris Technologies Global
Company profileAnteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Wayne Geoffrey Paterson
- Headquarters
- Toowong, QLD
- Employees
- 174
- IPO year
- 2024
- Website
- anteristech.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$14.00+105.28%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 12, 2026
AVR news
All AVR newsAnteris Technologies Global peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CTKBCytek Biosciences Inc. | 5.34 | -0.74% | $694.11M | vs AVR |
| KIDSOrthoPediatrics Corp. | 22.48 | -1.01% | $586.95M | vs AVR |
| SSIISS Innovations International Inc. | 2.74 | -0.72% | $548.00M | vs AVR |
| VREXVarex Imaging Corporation | 18.44 | -0.22% | $783.03M | vs AVR |
| AHCOAdaptHealth Corp. | 5.88 | +1.91% | $784.45M | vs AVR |
| DCTHDelcath Systems Inc. | 15.38 | -0.19% | $533.67M | vs AVR |
| INMDInMode Ltd. | 14.01 | +0.14% | $806.19M | vs AVR |
| TCMDTactile Systems Technology Inc. | 22.02 | -0.77% | $498.80M | vs AVR |
Indexes, lists and sector
Appears in lists
Anteris Technologies Global stock FAQ
What is Anteris Technologies Global's stock price today?
AVR last traded at $6.82 as of Oct 7, 4:00 PM EDT, down 3.26% on the day. Prices are delayed at least 15 minutes.
When is Anteris Technologies Global's next earnings date?
Anteris Technologies Global is expected to report earnings on Thursday, November 12, 2026.
Who is Anteris Technologies Global's CEO?
Mr. Wayne Geoffrey Paterson is the chief executive officer of Anteris Technologies Global Corp., which has about 174 employees.
What is the AVR 52-week high?
The 52-week high for AVR is $11.06 and the 52-week low is $3.30. The stock is currently 38.3% below its high.